- Home
- GDTC vs CVKD Comparison
GDTC vs CVKD Comparison
Compare GDTC & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- CVKD
- Stock Information
- Founded
- GDTC 2018
- CVKD 2022
- Country
- GDTC Singapore
- CVKD United States
- Employees
- GDTC N/A
- CVKD N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- GDTC Health Care
- CVKD Health Care
- Exchange
- GDTC Nasdaq
- CVKD Nasdaq
- Market Cap
- GDTC 21.5M
- CVKD 29.5M
- IPO Year
- GDTC 2023
- CVKD 2023
- Fundamental
- Price
- GDTC $1.91
- CVKD $10.81
- Analyst Decision
- GDTC Buy
- CVKD Strong Buy
- Analyst Count
- GDTC 1
- CVKD 1
- Target Price
- GDTC $5.00
- CVKD $32.00
- AVG Volume (30 Days)
- GDTC 18.1K
- CVKD 28.9K
- Earning Date
- GDTC 01-01-0001
- CVKD 08-06-2025
- Dividend Yield
- GDTC N/A
- CVKD N/A
- EPS Growth
- GDTC N/A
- CVKD N/A
- EPS
- GDTC N/A
- CVKD N/A
- Revenue
- GDTC $368,838.00
- CVKD N/A
- Revenue This Year
- GDTC $5.37
- CVKD N/A
- Revenue Next Year
- GDTC N/A
- CVKD N/A
- P/E Ratio
- GDTC N/A
- CVKD N/A
- Revenue Growth
- GDTC N/A
- CVKD N/A
- 52 Week Low
- GDTC $1.20
- CVKD $5.70
- 52 Week High
- GDTC $4.05
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- GDTC 35.89
- CVKD 38.21
- Support Level
- GDTC $1.85
- CVKD $11.25
- Resistance Level
- GDTC $1.95
- CVKD $11.88
- Average True Range (ATR)
- GDTC 0.10
- CVKD 0.76
- MACD
- GDTC -0.02
- CVKD -0.02
- Stochastic Oscillator
- GDTC 23.53
- CVKD 7.46
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.